

0300

LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICHA NAND  
MICHAEL PHILLIPPS \*  
LISA M. DIROCCO  
HATHAWAY P. RUSSELL \*\*  
MARIA LACCOTRIPE-ZACHARAKIS, Ph.D.  
PETER A. DIMATTIA  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPERT

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
DANIEL B. KO

TECHNICAL SPECIALISTS  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFELD  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
JACOB G. WEINTRAUB  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only  
\*\* Admitted in TX only

May 21, 2002

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202

Re: U.S. Patent Application Serial No. 09/726,470  
Title: p21 PEPTIDES  
Filed: November 29, 2000  
Inventors: Daniella I. Zveleva *et al.*  
Attorney Docket No.: CCI-014


Dear Sir:

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages);
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure (1 page);
3. Diskette Containing Sequence Listing; and
4. A Pre-Paid Acknowledgment Postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed.


**Certificate of First Class Mailing (37 CFR 1.8(a))**

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on:

May 21, 2002  
Date  
  
Cynthia L. Kanik, Ph.D., Reg. No. 37,320

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

  
Cynthia L. Kanik, Ph.D.  
Reg. No. 37,320  
Attorney for Applicants

# 11

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of: Daniella I. Zheleva, et al.

Serial No.: 09/726,470

Filed: November 29, 2000

For : p21 Peptides

Attorney Docket No.: CCI-014



Group Art Unit: 1646

Examiner:

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202


**Certificate of First Class Mailing (37 CFR 1.8(a))**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date set forth below.

May 21, 2002

Date of Signature and of Mail Deposit

By:

  
Cynthia L. Kanik, Ph.D.  
Reg. No. 37,320  
Attorney for Applicants

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**


Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed from the U.S. Patent Office on March 21, 2002, enclosed is a diskette which contains a computer readable form of the Sequence Listing filed for the above-identified patent application. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on the enclosed diskette is identical in substance to the Sequence Listing

filed in the above above-identified patent application. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d). No new matter has been added.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Cynthia L. Kanik, Ph.D.  
Registration No. 36,207  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400  
(617) 742-4214

Date: May 21, 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/726,470	11/29/2000	Daniella I. Zheleva	CCI-014

000959  
LAHIVE & COCKFIELD  
28 STATE STREET  
BOSTON, MA 02109



CONFIRMATION NO. 1635

## FORMALITIES LETTER



\*OC000000007690808\*

Date Mailed: 03/21/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

A copy of this notice **MUST** be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

CDNL FELCA STANDARD; PRT: 164 AA.  
AC Q19602: 13-DEC-1998 (Rel. 37, Created)  
DT 15-DEC-1998 (Rel. 37, Last sequence update)  
DT 15-DEC-1998 (Rel. 37, Last annotation update)  
DE Cyclin-dependent kinase inhibitor 1 (p21) (CDK-interacting protein 1).  
GN CDKN1A OR CIP1 OR WAF1.  
OS Felis silvestris catus (Cat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.  
OX NCBI\_TaxID=9685;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Lymph node;  
RX MEDLINE=98036042; PubMed=9370275;  
RA Okuda M., Minehata K., Setoguchi A., Cho K.-W., Nakamura N.,  
RA Nishigaki K., Watarai T., Cevario S., O'Brien S.J., Tsujimoto H.,  
RA Hasegawa A.;  
RT "Cloning and chromosome mapping of the feline genes p21WAF1 and  
p27Kip1".  
RL Gene 198:141-147(1997).  
CC -!- FUNCTION: MAY BE THE IMPORTANT INTERMEDIATE BY WHICH P53 MEDIATES  
CC ITS ROLE AS AN INHIBITOR OF CELLULAR PROLIFERATION IN RESPONSE TO  
CC DNA DAMAGE. MAY BIND TO AND INHIBIT CYCLIN-DEPENDENT KINASE  
CC ACTIVITY, PREVENTING PHOSPHORYLATION OF CRITICAL CYCLIN-DEPENDENT  
CC KINASE SUBSTRATES AND BLOCKING CELL CYCLE PROGRESSION (BY  
CC SIMILARITY).  
CC -!- SUBCELLULAR LOCATION: Nuclear.  
CC -!- SIMILARITY: THE N-TERMINAL OF CIP1 AND KIP ARE SIMILAR.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL: D84650; BAA23168.1;  
DR InterPro: IPR003175; CDI.  
DR Pfam: PF02234; CDI; 1.  
KW Cell cycle; Nuclear protein; Zinc-finger.  
FT ZN\_FING 13 41  
FT DOMAIN 141 156 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).  
SQ SEQUENCE 164 AA; 18315 MW; 0F7912A76C78BF38 CRC64;

Query Match 92.7%; Score 38; DB 1; Length 164;  
Best Local Similarity 87.5%; Pred. No. 0.11;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8  
|:|||||  
Db 152 HSKRRLIF 159

Cyclin kinase inhibitor - human (fragments)  
C:Species: Homo sapiens (map)  
C:Date: 25-Feb-1994 #sequence\_revision 17-Nov-1995 #text\_change 17-Mar-1999  
C:Accession: S39358  
R:Xiong, Y.; Hannon, G.J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D.  
Nature 366, 701-704, 1993  
A:Title: p21 is a universal inhibitor of cyclin kinases.  
A:Reference number: S39357; MUID:94081955; PMID:8259214  
A:Accession: S39358  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-47 <XIO>

Query Match 92.7%; Score 38; DB 2; Length 47;  
Best Local Similarity 87.5%; Pred. No. 0.28;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8  
|:|||||  
Db 38 HSKRRLIF 45

#### RESULT 2

154380  
cyclin-dependent kinase - human (fragment)  
C:Species: Homo sapiens (man)  
C:Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 21-Jul-2000  
C:Accession: 154380  
R:Mousses, S.; Ozelik, H.; Lee, P.D.; Malkin, D.; Bull, S.B.; Andrulis, I.L.  
Hum. Mol. Genet. 4, 1089-1092, 1995  
A:Title: Two variants of the CIP1/WAF1 gene occur together and are associated with h  
A:Reference number: 154380; MUID:95384154; PMID:7655464  
A:Accession: 154380  
A:Status: preliminary; translated from GB/EMBL/DDBJ  
A:Molecule type: mRNA  
A:Residues: 1-181 <RES>  
A:Cross-references: GB:L47232; NID:984723; PIDN:AAB59559.1; PID:9984724  
C:Genetics:  
A:Gene: CIP1/WAF1

Query Match 92.7%; Score 38; DB 2; Length 181;  
Best Local Similarity 87.5%; Pred. No. 0.98;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8  
|:|||||  
Db 169 HSKRRLIF 176

#### RESULT 1

Q14010  
ID Q14010 PRELIMINARY; PRT: 181 AA.  
AC Q14010;  
DT 01-NOV-1996 (TRENBLrel. 01, Created)  
DT 01-NOV-1996 (TRENBLrel. 01, Last sequence update)  
DT 01-DEC-2001 (TRENBLrel. 19, Last annotation update)  
DE Cyclin-dependent kinase (Fragment).  
GN CIP1/WAF1.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=TUMOR;  
RX MEDLINE=95384154; PubMed=7655464;  
RA Mousses S., Ozelik H., Lee P.D., Malkin D., Bull S.B., Andrulis I.L.;  
RT "Two variants of the CIP1/WAF1 gene occur together and are associated  
RT with human cancer."  
RL Hum. Mol. Genet. 4:1089-1092(1995).  
DR EMBL: L47232; AAB59559.1;  
DR InterPro: IPR003175; CDI.  
DR Pfam: PF02234; CDI; 1.  
KW Kinase.  
FT NON\_TER 1  
SQ SEQUENCE 181 AA; 20083 MW; 4CCFA511232D4F1 CRC64;

Query Match 92.7%; Score 38; DB 4; Length 181;  
Best Local Similarity 87.5%; Pred. No. 1.8;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8  
|:|||||